BIS

Featured

Impressive Bull Run in Biotech ETFs Causes Some to Take Pause

By Tom LydonJuly 16, 2015

Featured

Volatility in Healthcare ETFs Ahead of Supreme Court’s Obamacare Ruling

By Tom LydonJune 15, 2015

Featured

A Tough Spot for Biotech ETFs

By Todd ShriberApril 28, 2015

Featured

Getting it Right (and Wrong) With Leveraged Biotech ETFs

By Todd ShriberMarch 25, 2015

Featured

ProShares to Reverse Split 10 Inverse, Leveraged ETFs

By Tom LydonOctober 15, 2014

Alternative ETFs

Most Searched ETFs: All Over the Map

By Todd ShriberSeptember 6, 2014

Featured

After a Rally, Biotech ETF Faces Resistance

By Todd ShriberJune 11, 2014

Alternative ETFs

Most Searched ETFs: Some Changes, but a few Surprises

By Todd ShriberApril 12, 2014

Featured

Biotech Bumble: ETFs Fall to 2014 Lows

By Todd ShriberApril 10, 2014

Featured

Investors Say Bye-Bye to Biotech ETFs

By Todd ShriberApril 8, 2014

Equity ETFs

Most Searched ETFs: A Global Flare

By Todd ShriberApril 5, 2014

Featured

Inverse Biotech Suddenly Cool Kid at ETF Party

By Max ChenApril 4, 2014

Featured

Biotech ETFs Hold Their Breath

By Max ChenMarch 28, 2014

Featured

A Gutsy Technical Call on a Biotech ETF

By Tom LydonMarch 27, 2014

Featured

Not Just Biotech: Other Momo ETFs Taken to Task

By Tom LydonMarch 24, 2014

Featured

Overlooked Bearish Biotech ETF Grows Up…Sort Of

By Todd ShriberMarch 21, 2014

Featured

Dissipate the Risk In Biotechnology With ETFs

By Tom LydonJanuary 18, 2011

Featured

New ETFs: Single-Country Small-Caps and Leveraged Biotech

By Tom LydonApril 15, 2010